THIOPHANATE-METHYL First draft prepared by J. Taylor and M. Watson Pesticides Safety Directorate, Ministry of Agriculture, Fisheries and Food Mallard House, Kings Pool, York, United Kingdom Explanation Evaluation for acceptable daily intake Biochemical aspects Absorption, distribution, and excretion Biotransformation Effects on enzymes and other biochemical parameters Toxicological studies Acute toxicity Short-term toxicity Long-term toxicity and carcinogenicity Reproductive toxicity Developmental toxicity Genotoxicity Special studies Dermal and ocular irritation and dermal sensitization Effects on the thyroid and liver Observations in humans Comments Toxicological evaluation References Explanation Thiophanate-methyl is a systemic fungicide of the benzimidazole group. It was evaluated toxicologically by the Joint Meeting in 1973, 1975, and 1977 (Annex I, references 20, 24, and 28). The ADI of 0-0.08 mg/kg bw allocated in 1973 was confirmed by the 1975 and 1977 Joint Meetings. Since that time, additional data have become available, and the results of these studies were reviewed at the present Meeting. In order to facilitate review of the complete database, information presented in the reports of the previous monographs (Annex I, references 21, 25, and 29) are included in this monograph. Thiophanate-methyl was reviewed by the present Meeting within the periodic review programme of the CCPR. Evaluation for acceptable daily intake 1. Biochemical aspects (a) Absorption, distribution, and excretion In a series of studies, an unspecified number of male dd-Y strain mice were given a single dose of radiolabelled thiophanate-methyl by gavage. Four radiolabelled thiophanate-methyl moieties were used, 14C-carbonyl thiophanate-methyl, 35S-thiophanate-methyl, 14C-methyl thiophanate-methyl, and 14C-phenyl thiophanate-methyl. Faeces, urine, and expired gas were analysed 3, 6, 12, 24, 48, 60, 72, 84, and 96 h after administration, and blood samples were analysed after 3, 6, 12, 24, 48, and 72 h. Conjugates were determined after hydrolysis with hydrochloric acid or ß-glucuronidase. An unspecified number of mice were killed 3, 6, 12, 24, 48, and 72 h after administration, and tissue samples were analysed for radiolabel. The contents of all moieties in blood and urine declined steadily from peak levels within 3 h, and faecal excretion peaked at about 12 h in all cases, declining significantly by 48 h. The rate of excretion varied slightly between moieties, but total excretion had reached a plateau at about 24 h. 14C-Methyl thiophanate-methyl showed a different pattern of excretion, suggesting that the methyl group was parted from the parent molecule and was rapidly absorbed and partially converted to carbon dioxide. Total excretion is summarized in Table 1. Table 1. Percentage of radiolabelled thiophanate-methyl excreted by male dd-Y mice after 96 h Compound Total radiolabel excreted (%) Total recovery (%) of radiolabel by day 4 or 5 Urine Faeces Expired gas 14C-Carbonyl thiophanate-methyl 78-83 18-20 ND 102 (day 5) 35S-Thiophanate-methyl 66-86 19-21 ND 105 (day 5) 14C-Methyl thiophanate-methyl 66-67 16-17 1 ND 14C-Phenyl thiophanate-methyl 78-89 27-29 ND 117 (day 4) ND, not determined None of the moieties accumulated in any organ or tissue, and radiolabel disappeared relatively rapidly within the 96-h investigation period. After three days, 14C-carbonyl thiophanate- methyl radiolabel was detectable in liver and blood, 14C-methyl thiophanate-methyl radiolabel primarily in liver, kidney, and blood, and 14C-phenyl thiophanate-methyl radiolabel in liver, with low levels in a number of tissues. 35S-Labelled thiophanate-methyl was the only moiety found in bone after 96 h, suggesting that the labelled sulfur might be cleaved and hence behave differently. Metabolites were investigated in urine, faeces, organs, and tissues by thin-layer chromatography. Untreated urine from 14C-phenyl thiophanate-methyl produced eight possible metabolites. The parent molecule and three metabolites were identified against known standards: carbendazim, an intermediate (1-thioureido-2-(3-ethoxycarbonyl-2-thioureido)benzene), and a minor metabolite (1,2-bis(3-ethoxycarbonyl-2-ureido)benzene). Hydrolysis of the water-soluble fraction with hydrochloric acid or ß-glucuronidase resulted in six spots, the majority of which were identified as carbendazim and its hydroxy analogue 5-hydroxy- carbendazim, which were found by co-chromatography with authentic standards to be glucuronic acid conjugates. 1-Thioureido-2- (3-ethoxycarbonyl-2-thioureido)benzene and 1,2-bis(3-ethoxy- carbonyl-2-ureido)benzene were also found, but two further metabolites were not identified. Faeces, liver, kidney, stomach, and intestine were also investigated for metabolites. Thiophanate-methyl, carbendazim, 5-hydroxy-carbendazim, and 1-thioureido-2-(3-ethoxy- carbonyl-2-thioureido)benzene were identified in faeces; the parent molecule, carbendazim, 5-hydroxycarbendazim, and 1,2-bis(3-ethoxy- carbonyl-2-ureido)benzene were identified in liver; carbendazim, 5-hydroxycarbendazim, and 1,2-bis(3-ethoxycarbonyl-2-ureido)benzene were identified in kidney; the parent molecule was the main compound identified in stomach, with small amounts of carbendazim and 1,2-bis(3-ethoxycarbonyl-2-ureido)benzene; and the parent molecule and carbendazim were identified in the intestine (Noguchi, 1970a, 1971, 1972; Fujino et al., 1973). An unspecified number of male Wistar rats were given a single dose of 14C-thiocarbonyl]-thiophanate-methyl by gavage. Most of the radiolabel (83% of the total administered) was excreted within 24 h, with 56% in faeces and 28% in urine. By 72 h, 89% of the label had been excreted. Table 2 shows the 24-h faecal and urinary metabolites that were characterized. Of the 56% radiolabel detected in the faeces, 1% in the water-soluble phase was uncharacterized and > 4% remained in the residue; of the 28% radiolabel in urine, 14% was uncharacterized because it was not extractable (Fujino et al., 1973). Table 2. Recovery of 14C-labelled compounds in rat urine and faeces 24 h after administration of 14C-labelled thiophanate-methyl Compound Recovery (as % of administered 14C-labelled thiophanate-methyl) Faeces Urine Thiophanate-methyl 38 1 4-Hydroxy-thiophanate-methyl 6 3 5-Hydroxy-carbendazim 2 6 4-Hydroxy-dimethyl-4,4'-O-phenylene bisallophanate 1 2 Dimethyl-4,4'-O-phenylene bisallophanate 1 2 Carbendazim 1 1 An unspecified number of male beagle dogs were given a single dose of [14C-carbonyl]-thiophanate-methyl in a capsule. Blood, urine, and faeces were collected 8, 15, and 30 min and 1, 2, 3, 6, 12, 24, 35, 48, 60, 72, and 96 h after administration. Urine contained 74% of the total radiolabel and faeces, 14%. Maximal total excretion occurred after about 24 h by both routes. The total recovery of radiolabel was not specified. Carbendazim was identified by co-chromatography from urine samples. Treatment of urine samples with ß-glucuronidase released the 5-hydroxy analogue. No other metabolites were identified (Noguchi, 1972; Fujino et al., 1973). (b) Biotransformation Male mice (strain unspecified) received 0.1 g/kg bw of an aqueous thiophanate-methyl solution orally, and their urine and faeces were collected at 24, 48, and 72 h. Metabolites were extracted into ethylacetate; conjugated metabolites were extracted by enzymic hydrolysis with ß-glucuronidase and arylsulfatase. As a proportion of the total dose administered, 27% was identified as free metabolites in urine, the majority (19%) being carbendazim; other metabolites, 2-aminobenzimidazole (2.5%), 5-hydroxy-2-aminobenzimidazole (0.4%), and 5-hydroxycarbendazim (4.9%), accounted for the other 8% found free in urine. Conjugates of glucuronide and/or sulfate were found in urine and faeces, but the amounts of each type were not determined and only two were identified (representing 8% of total dose), of which 6% was 5-hydroxycarbendazim and 2% aminobenzimidazole. In faeces, 16% of the administered dose was identified as free metabolites, carbendazim again being prevalent (11%); 2-amino-benzimidazole (3%), 5-hydroxy- 2-aminobenzimidazole (0.3%), and 5-hydroxy carbendazim (3%) accounted for the other 6% found free in faeces. Of the total dose 8% was identified as conjugated metabolites, with similar proportions of the two metabolites found in urine. Thin-layer chromatography of faeces and urine showed the presence of 10 conjugated metabolites. Mouse liver preparations were incubated with 1 mmol/litre thiophanate-methyl, and 11 metabolites were identified: 2-(3-methoxycarbonyl-2-thioureido)aniline, 1-(3-methoxycarbonyl-2-ureido)-2-(3-methoxycarbaryl-2-thioureido) benzene, 1,2-bis(3-methoxycarbonyl-2-ureido)benzene, 2-(3-methoxycarbonyl-2-ureido)aniline, 1-thioureido-2-(3-methoxycarbonyl-2-thioureido)benzene, 1-(2-ureido)-2-(3-methoxy-2-thioureido)benzene, 1-(2-ureido)-2-(3-methoxycarbonyl-2-ureido)benzene, 2-aminobenzimidazole, 5-hydroxy-2-aminobenzimidazole, methylbenzimidazole-2-ylcarbamate (carbendazim), and methyl 5-hydroxybenzimidazol-2-ylcarbamate (5-hydroxy- carbendazim). Incubation with mouse kidney and brain preparations produced similar metabolites, with thin-layer chromatography patterns that were indistinguishable under fluorescence quenching. Incubation with intestinal preparations did not produce cyclized benzimidazole derivatives, but 2-(3-methoxycarbaryl-2-thioureido) aniline and 1-thioureido-2-(3-methoxycarbaryl-2-thioureido)benzene were detected. Further experiments were carried out in vitro with non-cyclized compounds (including the 11 thiophanate-methyl metabolites identified) as the substrate in mouse liver preparations. The rate of carbendazim formation from eight compounds, including thiophanate-methyl, was measured. The 11 metabolites were relatively stable but 1-formamido- 2-(3-methoxy-2-thioureido)benzene and the 2-ureido analogue were relatively unstable to nonenzymatic transformation. Formation of carbendazim was rapid for substrates with an intact 3-ethoxy-carbonyl- 3-thioureido constituents, although the formamide and thioformamide derivatives showed highest cyclization (the latter being cyclized at about 80% of the former). The largest amounts of 2-aminobenzimidazole were formed from substrates containing thioureido or ureido side-chains. Formation of 2-aminobenzimidazole was 25-50% that of carbendazim. Hydrolysis of carbendazim with subsequent cyclization was proposed. Additional experiments to investigate the cofactor (NAD, NADP, and glucose-6-phosphate) requirements for reactions leading to carbendazim suggested that mixed-function oxidase enzymes were responsible, as these reactions were inhibited by carbon monoxide and SKF 525A (Douch, 1974). 14C-Thiocarbonyl-labelled thiophanate-methyl was added to liver microsome preparations from homogenates obtained from male and female Sprague-Dawley rats fed either a commercial diet or a diet containing 640 ppm thiophanate-methyl for three months. No sex difference and no enzyme induction were seen; only one metabolite, carbendazim, was identified, by thin-layer co-chromatography (Noguchi, 1970b). Male and female Sprague-Dawley rats were fed either a commercial diet or a diet containing 640 ppm of 14C-carbonyl thiophanate- methyl, 35S-thiophanate-methyl, 14C-methyl thiophanate-methyl, or 14C-phenyl thiophanate-methyl for three months. No sex difference and no enzyme induction was seen. Four metabolites of the 14C moieties were identified by autoradiography: dimethyl-4,4'- O- phenylenebisallophanate, an intermediate metabolite, carbendazim, and 5-hydroxycarbendazim; 35S-thiophanate-methyl did not result in carbendazim (Noguchi, 1972). In a similar study, 4-hydroxythio- phanate-methyl and dimethyl-4,4'- O-phenylene bisallophanate were identified in vitro as metabolites of thiophanate-methyl in rat liver microsome preparations (Fujino et al., 1973). A proposed metabolic pathway for thiophanate-methyl is presented in Figure 1. (c) Effects on enzymes and other biochemical parameters A number of experiments were performed on mice, rats, and rabbits to determine the pharmacological properties of thiophanate-methyl (purity, > 98%) (Singh & Garg, 1989). The results are summarized in Table 3. 2. Toxicological studies (a) Acute toxicity The acute toxicity of thiophanate-methyl is summarized in Table 4. It has little acute toxicity. At high oral doses in older studies, the active ingredient induced symptoms of toxicity which included tremors and tonic and clonic convulsions. In a newer study with thiophanate-methyl of 96.55% purity, there were no signs of toxicity or deaths at 5000 mg/kg bw orally (Souma & Nishibe, 1990a). After acute inhalation of 95.3% pure compound at concentrations close to the LC50 (1.7-1.9 mg/litre), the symptoms of toxicity included ataxia, decreased motor activity, tremor, and convulsions (Saika & Nishibe, 1987).Table 3. Pharmacological effects of thiophanate-methyl Parameter Species Dose and route Results Body temperature Wistar rats 380-1500 mg/kg bw orally No effect Analgesic activity Mice 500 mg/kg bw intraperitoneally No effect Sedative or hypnotic activity Rats and mice 100-500 mg/kg bw subcutaneously No effect Cardiovascular and respiratory Rabbits 20-100 mg/kg bw intravenously Reduced blood pressure effects followed by bradycardia Table 4. Acute toxicity of thiphanate-methyl Species Sex Route LD50 or LC50 Reference (mg/kg bw or mg/litre air) Mouse Male, female Orala 3400-3514 Noguchi & Hashimoto (1970a) Mouse Male, female Intraperitoneal 792-1113 Noguchi & Hashimoto (1970a) Mouse Male, female Subcutaneous > 10 000 Noguchi & Hashimoto (1970a) Mouse Male, female Dermal > 10 000 Noguchi & Hashimoto (1970a) Rat Male, female Oral 6640-7500 Noguchi & Hashimoto (1970a) Rat Male, female Intraperitoneal 140-1640 Noguchi & Hashimoto (1970a) Rat Male, female Subcutaneous > 10 000 Noguchi & Hashimoto (1970a) Rat Male, female Dermal > 10 000 Noguchi & Hashimoto (1970a) Rat Male, female Inhalation 1.7-1.9 Nishibe (1987) Rat Male, female Oralb > 5000 Souma & Nishibe (1990a) Guinea-pig Male, female Oral 3640-6700 Noguchi & Hashimoto (1970a) Guinea-pig Male, female Dermal > 10 000 Noguchi & Hashimoto (1970a) Rabbit Male, female Oral 2270-2500 Noguchi & Hashimoto (1970a) Rabbit Male, female Dermal > 10 000 Noguchi & Hashimoto (1970a) Rabbit Male, female Dermalb > 2000 Souma & Nishibe (1990b) a In gum arabic in 5% sodium chloride solution b In distilled water c Mortality rates: 0 at 350 mg/kg bw per day, 2 at 500 mg/kg bw per day, 1 at 650 mg/kg bw per day, 0 at 800 mg/kg bw per day, 3 at 1100 mg/kg bw per day, and 3 at 1400 mg/kg bw per day (b) Short-term toxicity Mice Groups of 12 ICR mice of each sex were fed diets containing thiophanate-methyl at doses of 0, 12.8, 64, 320, 1600, or 8000 ppm for six months. The homogeneity, stability, and concentrations of the diet were not reported; clinical signs of toxicity were also not reported. There were no treatment-related deaths. The body-weight gain of animals of each sex at 8000 ppm was significantly reduced. Erythrocyte counts were also reduced in these animals and in males at 1600 ppm, and haematocrit values were reduced in animals of each sex at 1600 and 8000 ppm. No significant differences were seen in the weights of the cerebrum, heart, lung, spleen, kidney, or testis, but in animals at 8000 ppm, liver weights were increased. Histopathological investigation revealed a higher incidence of hepatic-cell irregularity at the higher doses, with five cases in males and three in females at 8000 ppm and one case in an animal of each sex at 1600 ppm. Large swollen hepatic cells, some with oedematous or granular protoplasm, were found to a greater extent at 8000 ppm, especially in the central lobules. Constriction of veins by the swollen cells was proposed to explain the cloudy appearance of the liver. Sporadic formation of acidiphilic bodies from hepatic-cell degeneration was recorded in two females and one male at 8000 ppm and one male at 1600 ppm. The NOAEL was 320 ppm, equivalent to approximately 48 mg/kg bw per day, on the basis of hepatotoxic and haematological effects at 1600 and 8000 ppm (Noguchi & Hashimoto, 1970b; Hashimoto et al., 1973). Rats Groups of 12 Sprague Dawley rats of each sex were fed diets containing thiophanate-methyl at doses of 0, 12.8, 64, 320, 1600, or 8000 ppm for six months. The homogeneity, stability, and concentrations of the diet were not reported, and no clinical signs of toxicity were reported. There were no treatment-related deaths. The body-weight gain of animals of each sex at 8000 ppm was significantly reduced, but food consumption did not differ significantly between groups. Reduced erythrocyte counts were seen in animals of each sex at 8000 ppm. Urinalysis did not show significant treatment-related differences. Blood cholesterol levels were raised significantly in animals of each sex at 8000 ppm. The thyroid anti liver weights were increased in these animals, and the weight of the thymus was increased in females. Some histopathological effects on the thyroid were reported in animals at this dose: four animals of each sex had small thyroid follicles, four males and four females had thickened follicular epithelium, and five animals of each sex had decreased colloidal substance. There were no treatment-related effects on protein-bound iodine levels. The NOAEL was 1600 ppm, equivalent to approximately 80 mg/kg bw per day, mainly on the basis of effects on thyroid, liver, and body weights (Noguchi & Hashimoto, 1970c; Hashimoto et al., 1973). Dogs Groups of five beagle dogs of each sex (four at the highest dose) were fed capsules containing thiophanate-methyl (purity unspecified) at doses of 0, 2, 10, 50, or 250 mg/kg bw per day for two years. One animal of each sex at each dose was killed and autopsied after 12 months. There were no deaths or adverse symptoms. Animals of each sex at 250 mg/kg bw per day had reduced body weights and body-weight gain. Gross pathological effects were not reported, and no effects on the eyes or heart were found in periodic ophthalmoscopic and electro- cardiographic investigations. There were no treatment-related changes in clinical chemical, haematological, or urinary values. After 24 months, the weight of the thyroid gland was increased in animals of each sex at 250 mg/kg bw per day and to a lesser extent at 50 mg/kg bw per day. The effects on thyroid tissue at 12 months included altered or decreased colloidal substance and slightly taller cuboid follicular epithelial cells at 250 mg/kg bw per day. The NOAEL was 10 mg/kg bw per day on the basis of effects on thyroid weight in animals of each sex at 50 and 250 mg/kg bw per day (Taniguchi, 1972). Groups of four male and four female beagle dogs were fed capsules containing thiophanate-methyl (purity, 96.55%) for three months at doses of 0, 50, 200, or 800 mg/kg bw per day, the last dose being lowered to 400 mg/kg bw per day on test day 50 because of severe toxicity. One male at the high dose was sacrificed on day 41 because of severe toxicity; one male at 50 mg/kg bw per day died on day 36, but this death did not appear to be related to treatment. Dose-related clinical signs seen in animals at the high dose and to a lesser extent at the middle dose included dehydration, thinness, and lethargy. Dose-related decreases in body weights and marked decreases in food consumption were seen at the middle and high doses. There were no treatment-related ophthalmological findings. Slight anaemia, increased platelet counts and cholesterol levels, and decreases in serum alanine aminotransferase activity and albumin levels were seen at the middle and high doses and increased activated partial thromboplastin time at the high dose. Thyroid function tests revealed slightly decreased triiodothyronine levels in males at the high dose and decreased triiodothyronine and thyroxine levels in females at the middle and high doses; no clear effects on thyroid-stimulating hormone values were apparent. Urinalysis showed no treatment-related findings. At the middle and high doses, the weights of the liver (in animals of each sex) and thyroid (males only) were increased. Gross examination post mortem revealed emaciation in one male at the middle dose and three at the high dose. Dose-related histological alterations were seen in a number of organs. In thyroids, hypertrophy of the follicular epithelium was found in one, three, and four males and one, two, and four females at the low, middle, and high doses, respectively, with none in controls. The severity of the hypertrophy increased from minimal to marked with dose. Hyperplasia of the follicular epithelium was found in one male at the middle dose and in most animals at the high dose. In two males at the high dose in which both hypertrophy and hyperplasia were marked, a large decrease in the quantity of intrafollicular colloid was seen. In animals at the middle and high doses, dose-related changes were found in the liver (reduction in vesiculation of the hepatocellular cytoplasm), gall-bladder (intracytoplasmic vacuoles), pancreas (atrophy of acinar cells due to a decreased quantity of zymogen granules), spleen (lymphoid-cell depletion), thymus (involution), prostate (atrophy), uterus (anoestrus), and ovaries (inactive). There was no NOAEL because of the presence of follicular-cell hypertrophy in the thyroid of two dogs at the low dose (Auletta, 1991). Groups of four male and four female beagle dogs were fed capsules containing thiophanate-methyl (purity, 96.55%) at doses of 0, 8, 40, or 200 mg/kg bw per day for one year. There were no deaths. Tremors were seen in all dogs at the high dose 2-4 h after treatment on one or more occasions during the initial three weeks of the study but not subsequently. The tremors were slight to moderate, except in one animal which had severe tremors that progressed to apparent tonic convulsions on three occasions. The body-weight gains of animals at the high dose were reduced during the study, and body-weight losses were noted in the first week of treatment; slight reductions in body-weight gain were noted at 40 mg/kg bw per day. The food consumption of dogs at the high dose was generally lower than that of controls during the early months, but was close to the control value thereafter. Ophthalmological examinations and urinalyses showed no treatment-related effects. Haematological effects consisted of slight decreases in total erythrocyte counts and haemoglobin and haematocrit values in males at the high dose. These animals also had decreased serum alanine aminotransferase activity, increased alkaline phosphatase activity, increased cholesterol levels (also at the middle dose), and decreased albumin:globulin ratios (also at the middle dose), calcium (also at the middle dose), potassium, and phosphorus levels. In females at 200 mg/kg bw per day, serum alanine aminotransferase activity was decreased, and alkaline phosphatase activity and cholesterol levels were increased. Thyroid function tests revealed decreased thyroxine levels in males at the middle and high doses but no clear effects on triiodothyronine or thyroid-stimulating hormone. Abnormalities seen post mortem included increased liver weights in dogs at the high dose and increased thyroid weights in those at the middle and high doses. Microscopic alterations attributed to treatment were limited to minimal to moderate hypertrophy and slight hyperplasia of the follicular epithelium of the thyroid in the dogs at the middle dose (hypertrophy in two females) and the high dose (hypertrophy in four males and three females, and hyperplasia in one male and one female). The NOAEL was 8 mg/kg bw per day (Auletta, 1992). (c) Long-term toxicity and carcinogenicity Mice Groups of 50 ICR mice of each sex were fed diets containing 0, 10, 40, 160, or 640 ppm thiophanate-methyl (purity, > 94%) for two years. The homogeneity, stability, and concentrations of thiophanate-methyl in the diets were not reported. The body-weight gain of males at 640 ppm was reduced during the study. No treatment-related effects on food consumption or on mortality or overt signs of toxicity were seen. By 24 months, 74-94% of treated animals had died, but the mean survival times were comparable. Organ weights and clinical chemical and haematological parameters were not investigated. No treatment-related gross macroscopic or histopatho- logical alterations were seen, and there was no evidence of carcinogenicity. The NOAEL was 160 ppm, equivalent to about 24 mg/kg bw per day, on the basis of the reduction in body-weight gain in males at 640 ppm (Kosaka, 1973). Groups of 60 male and 60 female CD-1 mice were fed diets containing 0, 150, 640, 3000, or 7000 ppm thiophanate-methyl (purity, 95.9-96.6%) for 18 months. Ten animals of each sex in each group were necropsied after 39 weeks of treatment, and surviving animals were necropsied after 78-79 weeks of treatment; all mice that died or were killed in extremis were also autopsied. The homogeneity, stability, and concentrations of thiophanate-methyl were acceptable. Haemato- logical and thyroid function were assessed at the interim necropsy and before the end of the study. No treatment-related clinical signs were observed. The cumulative numbers of deaths up to 18 months of - treatment were 10, 11, 14, 16, and 24 males and 12, 13, 15, 17, and 23 females at 0, 150, 640, 3000, and 7000 ppm, respectively; animals at 7000 ppm had a significantly higher mortality rate than controls. The increased rates in females at 3000 ppm and males and females at 7000 ppm appeared to be related to amyloid deposition in tissues. Body-weight gains were slightly reduced in animals of each sex at 3000 ppm and to a greater degree at 7000 ppm; food consumption was slightly reduced in females at 3000 and 7000 ppm. There was no treatment-related effect on ophthalmologic parameters or on the onset or number of palpable masses. The only haematological parameter that appeared to be altered by treatment was a slightly lower erythrocyte count in males at 7000 ppm. At the nine-month interim necropsy, enlarged thyroid glands were seen grossly in three of 10 males at 7000 ppm, the thyroid weights of males and females at 3000 and 7000 ppm were increased, and the thyroid-stimulating hormone levels were higher and the thyroxine levels lower in males at 3000 ppm and males and females at 7000 ppm than in controls. The differences in thyroid weights and thyroid hormone levels were not seen at 18 months. At the nine-month interim necropsy, the liver weights of males and females at 3000 and 7000 ppm were significantly increased as a result of an increased incidence and severity of hepatocellular centrilobular hypertrophy at these two doses; the incidence of hepatocellular centrilobular hypertrophy was also increased in females at 640 ppm, five out of 10 having minimal hypertrophy. At 18 months, the mean liver weights of animals at 7000 ppm were increased as a result of a significantly increased number of liver masses, which was also significantly increased at 3000 ppm. At the 18-month terminal necropsy, an increased incidence of hepatocellular centrilobular hypertrophy was seen in males at 3000 and 7000 ppm. Histopathological examination revealed that the liver masses seen grossly were adenomas. The incidence of hepatocellular adenomas was significantly increased in males and females at 3000 and 7000 ppm. The slightly increased incidence of hepatocellular adenomas in females at 640 ppm (8.6%) was greater than the historical control range (0-2.7%). Two hepatocellular carcinomas were seen, one in a male at 640 ppm and the other in a male at 7000 ppm; this 2% incidence was similar to the mean incidence for historical control males (1.4%; range, 0-6%). One male at 7000 ppm had a hepatoblastoma, which is a relatively rare tumour (0.001% in historical controls). The incidence of atrial thrombosis was increased in females at 3000 ppm and in animals of each sex at 7000 ppm. The NOAEL was 150 ppm, equivalent to 29 mg/kg bw per day, in view of the possible treatment-related incidence of hepatocellular adenomas in females at 640 ppm (Tompkins, 1992). Rats Groups of 35 Sprague-Dawley rats of each sex (50 of each sex for controls) were fed diets containing thiophanate-methyl (purity, > 94%) at doses of 0, 10, 40, 160, or 640 ppm for two years. Five rats of each sex at each dose were killed and autopsied at three and 12 months. The homogeneity, stability, and concentrations of thiophanate-methyl in the diets were not reported. There were no treatment-related deaths, although survival was poor in some groups, and there were no overt signs of toxicity. Body-weight gain was reduced in animals of each sex at 640 ppm, but no significant difference in food consumption was observed. No significant treatment- related effects were seen on clinical chemical, haematological, or urinary values. No significant adverse histopathological effects or changes in organ weights were seen at any dose at three or 12 months. Necropsy of animals killed after 24 months or which died during treatment showed treatment-related histopathological findings in the testes and thyroid gland. Males at 640 ppm had an increased incidence of decreased colloidal substance and hypertrophy of follicular epithelium in thyroid tissue (6/35 compared to 1/50 in controls). Five animals at 640 ppm were found to be hypospermatogenic; one died at week 91 with a pituitary tumour and was found to have atrophied testes. Another male had diminished spermatogenesis at 24 months, and another surviving male and one that died during treatment had hyperplasia of the testicular interstitium. No other treatment-related effects were seen. There was no evidence for carcinogenicity. The NOAEL was 160 ppm, equivalent to about 8 mg/kg bw per day, on the basis of effects on the testes and thyroid gland and reduced growth at 640 ppm (Hashimoto, 1972). Groups of 60 male and 60 female Fischer 344 rats were fed diets containing 0, 75, 200, 1200, or 6000 ppm thiophanate-methyl (purity, 96.55%) for 24 months. The homogeneity, stability, and concentrations of thiophanate-methyl in the diets were acceptable. After 12 months, 10 rats of each sex in each group (only five males at 6000 ppm) were sacrificed. All survivors were sacrificed at the end of treatment. The mortality rates are shown in Table 5. Only two males at 6000 ppm survived to the end of the study; because of this high rate, no statistical analysis was performed for this group at 24 months. The main causes of death among these rats were nephropathy (22 rats), thyroid follicular-cell tumour (10 rats), and leukaemia (six rats); eight males at this dose died or were killed in extremis during weeks 11-12 due to fractures of the nasal bone caused by the feeder plate and subsequent dyspnoea (rhinorrhagia). The feeder plates were removed. No clinical signs attributable to treatment were noted in any group during the first 52 weeks. After week 52, dose-related clinical signs included pale skin and mucous membranes in males at 6000 ppm, alopecia in females at 6000 ppm, and tissue masses on the skin and in the subcutis including the lip in males at 1200 and 6000 ppm. These changes attained statistical significance at week 77 or later. Dose-related, statistically significant depressions in body-weight gain were noted in both males and females at 1200 and 6000 ppm. Decreased food consumption was seen in animals of each sex at 6000 ppm starting at week 76. No dose-related abnormalities were observed in ophthalmoscopic parameters at 6, 12, 18, or 24 months. Treatment- related signs of anaemia (decreased erythrocyte count, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, and mean corpuscular haemoglobin concentration) were seen in animals of each sex (mainly males) at 6000 ppm at 3, 6, 12, and 18 months. Increased platelet and leukocyte counts were seen frequently in males at 6000 ppm. Clinical chemical investigations revealed increased total cholesterol and total protein and decreased albumin:globulin ratios in animals of each sex at 1200 and/or 6000 ppm. At 24 months, treated males had increased blood urea nitrogen (at 75, 200, and 1200 ppm) and creatinine levels (at 1200 ppm), reduced thyroxine and triiod- othyronine values, and increased thyroid-stimulating hormone values (at 1200 and 6000 ppm, also in females at 6000 ppm). Dose-related increases in urinary protein (semi-quantitative analysis) were noted in animals of each sex at 6000 ppm at six and/or 12 months. Table 5. Mortality rates in Fischer rats treated with thiophanate-methyl Dose Male Female (ppm) Week 52 Week 80 Week 104 Week 52 Week 80 Week 104 No. % No. % No. % No. % No. % No. % 0 0/60 0 2/50 4 13/50 26 0/60 0 3/50 6 13/50 26 75 0/60 0 2/50 4 15/50 30 0/60 0 1/50 2 12/50 24 200 0/60 0 8/50 16 24/50 48* 0/60 0 1/50 2 8/50 16 1200 0/60 0 3/50 6 21/50 42 0/60 0 0/50 0 12/50 24 6000 8/60 13* 18/55 33** 53/55 96** 1/60 2 3/50 6 11/50 22 Significantly different from control at *P < 0.05; ** P < 0.001 (chi-square test) Nephelometry indicated an increase in urinary protein in males at 1200 and 6000 ppm at various times. Although males at 200 ppm had a statistically significant increase in urinary protein at 24 months, histopathological examination revealed no treatment-related effect. In males at 6000 ppm, ketone bodies, urinary volume, and water consumption were increased, and pH and specific gravity were decreased significantly at various times. Dose-related increases in the weights of the liver, kidney, and thyroid and their body-weight ratios were seen in animals of each sex at 1200 and/or 6000 ppm at both interim and final sacrifice. At interim sacrifice (week 53), treatment-related changes were found macroscopically in the liver (brownish-black) and kidneys (granular surface, brownish-black) of males and females at 6000 ppm. At final sacrifice, males at 1200 ppm had granular kidneys. Females at 6000 ppm also had enlarged thyroids. In animals at 6000 ppm that died during the study, swollen thyroids were seen in animals of each sex and white areas in the liver and granular kidney in males. Dose- related histopathological changes were found in the thyroid, liver, kidney, and adrenal: Thyroid follicular-cell hyperplasia and hypertrophy were noted in animals of each sex at 1200 and/or 6000 ppm at 12 and 24 months, and the incidence of focal follicular-cell hyperplasia was increased. Males at 6000 ppm also had a statistically significant increased incidence of thyroid follicular-cell adenomas (12/60), and one of two males at 6000 ppm that were killed at 24 months and 2/53 that were dead or were killed in extremis had thyroid follicular-cell adenocarcinomas, with none in the other groups of treated males. The incidence of retinal atrophy was increased in females at 6000 ppm at 24 months, and those of parathyroid hypertrophy and hyperplasia were increased in males at this dose. Centrilobular hepatocellular hypertrophy and lipofuscin deposition were noted in animals of each sex at 1200 and/or 6000 ppm at 12 and 24 months and in most males and females at 6000 ppm which died during the study. Microgranuloma and focal fatty degeneration in the liver were increased in incidence in males treated at 6000 ppm. Lipidosis of the adrenal cortex was noted in females at 1200 ppm and in animals of each sex at 6000 ppm at 12 months. The severity of nephropathy was increased in animals of each sex at 6000 ppm at 12 months and in those at 1200 and 6000 ppm at 24 months. Most males at 6000 ppm that died or were killed in extremis had severe nephropathy associated with hyperplasia of the parathyroid, demineralization of the bone, and metastatic calcification in various organs. The NOAEL was 200 ppm, equivalent to 8.8 mg/kg bw per day in males and 10.2 mg/kg bw per day in females. The increased blood urea nitrogen levels observed in males at 75 and 200 ppm and the increased urinary protein levels in males at 200 ppm at 24 months were not considered to be adverse effects in view of the absence of treatment-related pathological findings at these doses (Takaori, 1993). (d) Reproductive toxicity Mice Groups of eight male Swiss-Webster mice were given thiophanate- methyl (purity unspecified) as an oral dose of 192 mg/kg bw per day for five consecutive days. Twenty-four hours after the final dose [1,2-3H]-testosterone was administered intraperitoneally at 10 µCi/kg bw in order to assess its assimilation by the anterior prostate coagulating glands. Animals were killed after 5 min, and the anterior prostate glands were removed. Thiophanate-methyl did not significantly affect body weights, absolute testicular weights, absolute or relative seminal vesicular weights, or total radiolabel assimilation by the anterior prostate gland. The absolute prostate and adrenal gland weights were significantly increased, and these changes were considered by the authors to be due to stress induced by thiophanate-methyl. The relative weights of the testes, prostate, and adrenal were also increased. Spermatogenesis was not affected, no sterile tubules were seen, and the interstitial (Leydig) cells appeared to be normal (Thomas, 1974; Thomas & Schein, 1974). Rats In a three-generation study, groups of 10 male and 20 female weaning Sprague-Dawley rats fed diets containing 0, 40 160, or 640 ppm thiophanate-methyl (purity unspecified) were mated twice to produce the F1a and F1b litters. Ten male and 20 female offspring were selected from the F1b litters and mated to produce the F2a and F2b litters; 10 male and 20 female F2b offspring were then selected and mated to produce the F3a and F3b litters. The test diets were fed throughout the study, animals in the F0, F1b, and F2b generations being fed for 60 days before mating. In each case, mating lasted for 20 days. Animals were re-mated to produce the second litters about 10 days after weaning of the first litters. The homogeneity, stability, and concentrations of thiophanate-methyl in the diets were not reported. In F0 animals, no treatment-related effects on mortality, food consumption, or body-weight gain or clinical signs of toxicity were seen. No treatment-related effects were observed on mating performance, length of gestation, or pregnancy rate or at terminal autopsy in F0, F1b, or F2b rats. The total litter sizes and weights at birth were slightly reduced in all animals at 640 ppm except the F3a litter. Viable litter size and weight at weaning were reduced in all generations at 640 ppm; mean pup weight was not affected. Viable litter size and weight between birth and weaning were slightly reduced in the second F2b litter at all doses, the percentage losses increasing with dose; however, average pup weights were not affected. The total litter loss and the incidence of gross malformations of pups were not treatment-related. No dose-related effects were seen on macroscopic appearance, organ weight, histopathological parameters, or the skeleton in F3b offspring. The NOAEL was 160 ppm, equivalent to about 8 mg/kg bw per day, on the basis of effects on litters at 640 ppm (Palmer et al., 1972). In a two-generation study, groups of 25 male and 25 female Sprague Dawley rats were given diets containing thiophanate-methyl (purity, 95.93%) at doses of 0, 200, 630, or 2000 ppm. The homogeneity, stability, and concentrations of thiophanate-methyl in the diets were acceptable. After 14 weeks of treatment, the parental (F0) animals were mated for up to 21 days. The F0 females were allowed to litter and to rear their offspring (F1a generation) to weaning. After a 14-week maturation period after weaning, the parental F1 animals, selected from the F1a offspring, were mated for up to 21 days and the females were allowed to litter and rear their offspring (F2a generation) to weaning. After weaning of the F2a pups and review of the results of rearing and weaning, including high pup mortality in all groups, the F1 generation was mated again, six weeks after weaning of the surviving F2a pups. The F1 animals were allowed to mate for a maximum of 21 days with the same partner, as during the first mating, and to produce a second litter (F2b). The body-weight gain of males of the F0 generation and males and females of the F1 generation at 2000 ppm was reduced, but only the body-weight gain of male F1 animals at 630 ppm was affected. Food consumption was affected by treatment before the first mating and during the first and second gestations and first lactation only in F1 females at 2000 ppm. At this dose, the males and females of the F0 and F1 generations had elevated levels of thyroid-stimulating hormone; slightly reduced triiodothyronine levels were noted in F0 females at necropsy; and males and females of the F0 generation had lower thyroxine values at weeks 1 and 8 but not at necropsy. These findings are consistent with the histological findings and changes in organ weights found at this dose. Thyroid and liver weights were increased in male and female animals of the F0 and F1 generations at the high dose, and histopathological examinations of these animals showed treatment-related centrilobular hepatocyte hypertrophy in the liver and follicular-cell hypertrophy and hyperplasia (except in F1 females) in the thyroid. The weights of male and female F1a, male F2a, and male and female F2b pups were reduced at 2000 ppm; at 630 ppm, only the weights of male and female F2b pups were reduced. Very high pup losses, mainly after day 4 of lactation, occurred in all animals of the F2a generation, including the controls. No clear explanation was found for the pup losses. Those pups that did not die had normal postnatal development, except for reduced body-weight gain in male pups at the high dose. Such losses were not seen in the F2b groups. Functional tests of F1a, F2a, and F2b animals showed no treatment-related findings. The NOAEL was 630 ppm for male and female F0 animals, 200 ppm for the F1 generation, 630 ppm for the F1a and F2a offspring, and 200 ppm for the F2b offspring. The NOAEL was 2000 ppm for fertility and general reproductive performance (Muller, 1993). Since treatment-related histopathological effects were found in the thyroid and liver in rats at the high dose in the preceding study, organs from all F0 and F1 animals at 200 and 630 ppm were further evaluated. The incidence and severity of hepatocyte hypertrophy were increased in a dose-related fashion at all doses in F0 males, and the incidence and to a lesser extent the severity of thyroid follicular-cell hypertrophy and hyperplasia were increased in the same animals. F1 males also had increased (but to a lesser extent) hepatocyte hypertrophy and thyroid follicular cell hyperplasia at all doses. The minimal effect level was thus 200 ppm, equivalent to 9.7-14.7 mg/kg bw per day (Muller & Singer, 1995). (e) Developmental toxicity Mice Groups of 20 female ICR mice were given thiophanate-methyl (purity, 94%) at doses of 0, 40, 200, 500, or 1000 mg/kg bw per day by gavage on days 1-15 of gestation. Animals were killed on day 18 or 19 (discrepancy between the study report and publication). No deaths, abnormalities, or significant differences in body weights were recorded. The number of living fetuses per litter was reduced in animals at 1000 mg/kg bw per day, partly as a result of increased resorptions. No treatment-related effects were observed on implantation numbers, litter sizes, fetal body weights, sex ratio, or numbers of immature or malformed fetuses. The NOAEL was 1000 mg/kg bw per day for maternal toxicity and 500 mg/kg bw per day for embryo- and fetotoxicity, on the basis of the reduced number of live fetuses at 1000 mg/kg bw per day. There was no evidence of teratogenicity (Noguchi, 1970c; Makita et al., 1973). Rats Groups of 25 female Sprague-Dawley rats were given thiophanate-methyl (purity, 97.2%) at doses of 0, 100, 300, or 1000 mg/kg bw per day by gavage on days 6-19 of gestation. Animals were killed on day 20 of gestation. There were five to nine nongravid females per group, including the control group. One rat at 100 mg/kg bw per day and one at 300 mg/kg bw per day delivered on days 13 and 11, respectively, and were killed on the day of delivery. The weight and development of the offspring were comparable to those of animals delivered later, suggesting incorrect assessment of copulation; no malformations or maternal abnormalities were seen in these animals. No deaths, treatment-related clinical symptoms, or gross pathological abnormalities were reported in any dams. Body-weight gain was reduced between days 6 and 9 in animals at 1000 mg/kg bw per day. There were no treatment-related effects on total implantations, post-implantation loss, fetal body weight, fetal sex ratio, or viable fetuses. There were no dose-related fetal malformations or developmental abnormalities, and the incidences of these parameters were within those of historical controls. A positive control study in the same strain with a single high dose of vitamin A produced the appropriate results. The NOAEL was 300 mg/kg bw per day for maternal toxicity, on the basis of the reductions in body-weight gain of dams at 1000 mg/kg bw per day during treatment. There was no evidence of teratogenicity or embryo- or fetotoxicity (Rodwell et al., 1981). Rabbits Groups of 15 female New Zealand white rabbits received thiophanate-methyl (purity, 96.2%) at doses of 0, 2, 6, or 20 mg/kg bw per day by gavage on days 6-19 of gestation. Samples of test solutions were taken during the first and last weeks of treatment, and the concentrations of thiophanate-methyl were found to be acceptable. The animals were killed on day 29 of gestation. No treatment-related maternal mortality or clinical or subsequent maternal effects were seen. Dose-related losses in maternal body weight were observed mainly at the beginning of treatment (days 6-8 at 6 mg/kg bw per day and days 6-14 at 20 mg/kg bw per day). The food consumption of animals at 20 mg/kg bw per day was reduced from the start of treatment, and large reductions during days 6-12 were generally associated with subsequent abortion or sacrifice in extremis. Water consumption was unaffected. One of 12 animals at 2 mg/kg bw per day, one of 14 at 6 mg/kg bw per day, and two of 13 at 0 mg/kg bw per day aborted. One control animal and one at 20 mg/kg bw per day suffered total litter loss and resorption; the control animal suffered early resorption of its only implantation, while the treated animal lost five of five implantations. No treatment-related trends were observed in resorptions, pre- implantation losses, or fetal or placental weights. The numbers of viable young were slightly decreased in animals at 20 mg/kg bw per day due to abortions and total litter losses. Gross examination of the fetuses showed that in animals at 6 and 20 mg/kg bw per day, there was an apparent treatment-related trend in skeletal abnormalities in ribs, vertebrae, and pelvis that was generally close to or slightly greater than the upper limit of historical controls. Treatment-related effects included increased incidences of 13 pairs of ribs, incomplete or asymmetric ossification of costal elements of the sacral vertebrae, 27 presacral vertebrae, and asymmetric pelvises associated with different sacral vertebrae. At 20 mg/kg bw per day, the incidences of one or more ribs thickened at the costal cartilage were significantly increased. The frequencies of these skeletal abnormalities are summarized in Table 6. The NOAEL was 2 mg/kg bw per day for maternal toxicity, on the basis of the effect on maternal growth rate, and 2 mg/kg bw per day for developmental toxicity, on the basis of the increased incidence of skeletal abnormalities at 6 and 20 mg/kg bw per day (Ross et al., 1986). Table 6. Incidence of selected skeletal abnormalities in fetuses of rabbits treated with thiophanate-methyl Observation Dose (mg/kg bw per day) Historical controls 0 2 6 20 Mean Range 13 pairs of ribs 41 46 63 61 36 12-61 Thickened ribs 1 4 2 14 2 0-13 Incomplete or assymetrical 3 6 7 12 4 0-15 ossification 27 presacral vertebrae 16 18 38 43 18 7-44 Assymetrical pelvis 3 5 7 10 4 0-9 (f) Genotoxicity The results of studies of the genotoxicity and mutagenicity of thiophanate-methyl in vitro and in vivo are summarized in Table 7. There was no evidence of genotoxicity or mutagenicity. Thiophanate- methyl is partially metabolized in mammalian systems to carbendazim, which has been shown to act as an aneugen. The aneugenic potential of thiophanate-methyl (purity, 95%; dispersed in 70% kaolin) was tested in male Swiss albino mice given oral doses of 1000 mg/kg bw. Bone-marrow cells were analysed 16, 24, 36, and 48 h after treatment for micronuclei, chromosomal aberrations, hyperdiploidy, and polyploidy. Large micronuclei were significantly induced, but the response was relatively weak, and thiophanate-methyl was less effective than benomyl or carbendazim. There was no increase in the frequency of chromosomal aberrations. At 24 and 36 h, a possibly treatment-related increase in the frequency of polyploid and hyperdiploid cells was observed, which was of borderline significance in view of the very low frequency of changes in ploidy (Barale et al., 1993). Table 7. Results of tests for the genttoxicity of thiophanate-methyl End-point Test system Concentration Purity Results Reference or dose (%) In vitro Reverse mutation S. typhimurium TA98, 10, 50, 100, 97.3 Negativea Shirasu et al. (1976) TA100, TA1535, TA1537, 500, 1000 µg/plate TA1538, E. coli WP2 hcr dissolved in DMSO Reverse mutation S. typhimurium TA98, 39.1, 78.1, 156.3, 96.55 Negativea Kanaguchi & Nishibe TA100, TA1535, TA1537, 312.5, 625, 1250, (1990) E. coil WP2 uvrA 2500, 5000 µg/plate in DMSO Host-mediated S. typhimurium G46 1000, 3000 mg/kg 97.3 Negative Shirasu et al. (1976) mutation bw twice Gene mutation B. subtills H17, M45 20, 100, 200, 500, 97.3 Negative Shirasu et al. (1976) 1000, 2000 µg,/disk Gene mutation Chinese hamster V79 cells, 6.25, 12.5, 25.0, 50, 96.36 Negativea Tippins et al. (1984) hprt locus 100 µg/ml in DMSOa Chromosomal aberration Chinese hamster ovary cells 100, 200, 300, 400 95.0 Negative Murli (1988) µg/ml in DMSOa 250, 500, 750, 1000 µg/ml in DMSOb Unscheduled DNA Primary hepatocytes 5, 10, 25, 50, 100, 100 Negative Myhr (1981) synthesis 250, 500, 1000 µg/ml In vivo Dominant lethal mutation ICR mice 8-500 mg/kg bw 94 Negative Makita et al. (1973) intraperitoneally Cytogenicity Wistar rat bone marrow 62.5-1000 mg/kg bw 94 Negative Makita et al. (1973) and spermatocytes intraperitoneally DMSO, dimethyl sulfoxide a Without metabolic activation b With metabolic activation (g) Special studies (i) Dermal and ocular irritation and dermal sensitization Thiophanate-methyl (0.5 g; purity, 96.2%) moistened with water was applied to the backs of six male New Zealand white rabbits for 4 h under an occlusive patch. There were no signs of irritation over a 72-h observation period (Souma & Nishibe, 1986a). Nine male New Zealand white rabbits received 0.1 g thiophanate-methyl (purity, 96.2%) in the left eye. The treated eyes of three rabbits were washed with water, and those of the others remained unwashed. Conjunctival redness was observed in four of the unirrigated eyes and in all three of the irrigated eyes after 1 h. These symptoms had resolved by 24 h in all animals except one with an unwashed eye, in which irritation resolved by 48 h. Thiophanate-methyl was considered to be a very mild eye irritant (Souma & Nishibe, 1986b). The skin sensitizing potential of thiophanate-methyl (purity, 96.2%) was tested in 20 female Hartley guinea-pigs by the Magnusson-Kligman technique. Thiophanate-methyl was sensitizing under the conditions of the study (Souma & Nishibe, 1989). In a Buehler test, thiophanate-methyl (purity, 96.55%) was not sensitizing in 10 female Hartley guinea-pigs (Mochizuki, 1993). (ii) Effects on the thyroid and liver A number of studies were carried out to elucidate the effects of thiophanate-methyl on the thyroid and liver (Nishibe & Takaori, 1990). Thiophanate-methyl (purity, 96.55%) was administered in the diets of six-week-old male Fischer 344 rats for two or eight days at a concentration of 6000 ppm. Propylthiouracil, an inhibitor of thyroid hormone synthesis, was administered at 1000 ppm for two or eight days, and phenobarbital, an inducer of drug-metabolizing enzymes, was administered at 500 ppm for eight days, as positive controls. Thiophanate-methyl reduced triiodothyronine and thyroxine levels, increased thyroid-stimulating hormone activity (at day 8 only), increased thyroid weights (at day 8 only), and increased liver weights. Propylthiouracil caused similar but more marked changes in thyroid hormone levels and weights. Phenobarbital increased liver weights. All three chemicals increased serum cholesterol levels by day 8. Thiophanate-methyl and phenobarbital increased microsomal cytochrome P450, cytochrome b5, total protein, and UDP-glucu- ronosyltransferase activities. Seven-week-old female Fischer 344 rats were given 6000 ppm thiophanate-methyl or 500 ppm phenobarbital for eight days. Some were killed at eight days, and the others were killed after an eight-day recovery. Thyroid weights were increased at day 8. Groups of eight-week-old rats (sex not specified) were fed diets containing 0 or 6000 ppm thiophanate-methyl, 30 µg/kg bw thyroxine, or 6000 ppm thiophanate-methyl and daily injections of 30 µg/kg thyroxine subcutaneously, for eight days. Thiophanate-methyl caused hypertrophy of the thyroid and liver and increased the level of thyroid- stimulating hormone; these changes were suppressed by concomitant administration of thyroxine. Thiophanate with and without thyroxine also increased serum cholesterol. Thyroxine alone caused none of these changes. Thiophanate-methyl was less effective than propylthiouracil in inhibiting porcine thyroid microsomal peroxidase. The ED50 and ED0 were 6 × 10-4 mol/litre and 8 × 10-5 mol/litre for thiophanate- methyl and 2 × 10-5 mol/litre and 4 × 10-7 mol/litre for propylthiouracil. Eleven-week-old male ICR mice and Fischer 344 rats were given diets containing 6000 ppm thiophanate-methyl or 500 ppm phenobarbital for two or eight days. Liver weights were increased in all treated animals. The titre of hepatocyte proliferating cell nuclear antigen, the polymerase delta accessory protein, was increased in rats at day 2 and mice at days 2 and 8 (Nishibe & Takaori, 1990). 3. Observations in humans In 1969-72, 16 production workers continuously exposed to Topsin-E containing thiophanate or Topsin-M containing thiophanate- methyl were routinely tested for effects on health. Blood and urine samples were taken for analysis every six months: blood was analysed for erythrocyte and leukocyte counts, haemoglobin content, and specific gravity, and urine for protein, sugar, and urobilinogen. Serum alanine and aspartate aminotransferases activities were determined twice during the first six months of 1972 only. The initial tests were conducted in January 1969, prior to production of Topsin. No significant effects were seen in any of the workers for any of the parameters investigated (Mori, 1972). The same tests reported by Mori (1972) were conducted twice a year on 28 production workers exposed to Topsin M and/or Topsin E in 1973-77, except that leukocyte and erythrocyte counts and haemoglobin levels were not tested during 1976 for undescribed 'personal reasons'. Serum alanine and aspartate aminotransferase activities were determined in all employees in October 1977. More than 13 employees were tested each year, but the specific individuals tested changed during the study so that only seven individuals were monitored continuously. No adverse behavioural, haematological, clinical chemical, or urinary findings were made (Ikeda, 1978). Between 1985 and 1991, no adverse behavioural symptoms (including skin or eye effects) or clinical findings (haematology, clinical chemistry, or urinalysis) were observed in workers exposed to thiophanate-methyl and thiophanate during production. Health examinations were performed twice a year. The workers were involved mainly in the production of thiophanate-methyl, usually for 11 months of the year (Aizawa, 1991). Comments Thiophanate-methyl was rapidly absorbed after oral exposure of mice, rats, and dogs. Most of the administered radiolabel was recovered within 24 h of dosing, predominantly in the urine. Carbendazim and 5-hydroxycarbendazim were among the metabolites of thiophanate-methyl identified in vivo and in vitro. Thiophanate-methyl has low acute toxicity in rats, with an oral LD50 of about 7000 mg/kg bw. Clinical signs of toxicity after acute dosing with thiophanate-methyl were generally non-specific. WHO has classified thiophanate-methyl as unlikely to present an acute hazard in normal use. In a six-month study of toxicity, mice were given dietary doses of 0, 13, 64, 320, 1600, or 8000 ppm thiophanate-methyl. The NOAEL was 320 ppm, equivalent to 48 mg/kg bw per day, on the basis of haematological effects and hepatotoxicity. In a six-month study, rats were exposed to thiophanate-methyl in the diet at levels of 0, 13, 64, 320, 1600, or 8000 ppm. Reduced erythrocyte counts, reduced body-weight gain, and evidence of hepatotoxicity and thyroid stimulation were seen at 8000 ppm. The NOAEL was 1600 ppm, equivalent to 80 mg/kg bw per day. Dogs were exposed to thiophanate-methyl by administration in capsules at doses of 0, 50, 200, or 400 mg/kg bw per day for 13 weeks, 0, 8, 40 or 200 mg/kg bw per day for one year, or 0, 2, 10, 50, or 250 mg/kg bw per day for two years. Treatment-related thyroid hyperplasia was seen in all three studies; the overall NOAEL was 10 mg/kg bw per day. In a two-year study of carcinogenicity in mice fed dietary levels of 0, 10, 40, 160, or 640 ppm, there was no evidence of any carcinogenic response; the NOAEL was 160 ppm (equal to 24 mg/kg bw per day) on the basis of reduced body-weight gain. In a subsequent 18-month study in mice fed dietary levels of 0, 150, 640, 3000, or 7000 ppm, the NOAEL was 150 ppm (equal to 29 mg/kg bw per day) on the basis of treatment-related hepatotoxicity and hepatocellular tumours. In a two-year study of carcinogenicity in rats fed dietary levels of 0, 10, 40,160, or 640 ppm, effects were seen on the testes (mainly hypospermatogenesis), thyroid gland, and growth rate at 640 ppm; the NOAEL was 160 ppm (equivalent to 8 mg/kg bw per day). In a two-year study in rats fed dietary levels of 0, 75, 200, 1200, or 6000 ppm, the NOAEL was 200 ppm (equal to 9 mg/kg bw per day). Thyroid hyperplasia and thyroid tumours were seen at higher doses, together with parathyroid hyperplasia, nephrotoxicity, hepatotoxicity, and lipidosis of the adrenal cortex. In a three-generation study of reproductive toxicity in which rats received dietary doses of 0, 40, 160, or 640 ppm, reductions in total litter size and weight at birth and at weaning were seen at 640 ppm; the NOAEL was 160 ppm, equivalent to 8 mg/kg bw per day. In a two-generation study in which rats received dietary doses of 0, 200, 630 or 2000 ppm, there was no evidence of a treatment-related effect on reproduction. The lowest dose tested in the study, equivalent to 10 mg/kg bw per day, was a minimal-effect level on the basis of hepatocyte hypertrophy, thyroid follicular-cell hypertrophy, and hyperplasia at all treatment levels. The teratogenic potential of thiophanate-methyl was investigated in mice, rats, and rabbits. In mice exposed by gavage to thiophanate- methyl at doses of 0, 40, 200, 500, or 1000 mg/kg bw per day on days 1-15 of gestation, there was no evidence of teratogenicity or maternal toxicity at the highest dose, although embryo- and fetotoxicity were seen at this dose. In rats exposed by gavage to thiophanate-methyl at doses of 0, 100, 300, or 1000 mg/kg bw per day on days 6-19 of gestation, there was no evidence of fetotoxicity or teratogenicity, but maternal toxicity, expressed as reduced body-weight gain, was seen at the highest dose. In rabbits exposed by gavage to thiophanate- methyl at doses of 0, 2, 6, or 20 mg/kg bw per day on days 6-19 of gestation, maternal toxicity (reduced growth rate) was seen at 6 mg/kg bw per day and above. A dose-related trend of increased fetal skeletal abnormalities (ribs, vertebrae, and pelvis) at 6 and 20 mg/kg bw per day indicated an NOAEL for developmental toxicity of 2 mg/kg bw per day. Thiophanate-methyl was adequately tested for genotoxicity in a series of assays in vivo and in vitro. The only significant response was a small increase in the frequency of micronuclei characterized by their large size in mouse bone-marrow cells, which was not associated with the induction of structural chromosomal aberrations. This is indicative of a weak aneugenic effect. The Meeting concluded that thiophanate-methyl is not genotoxic. Studies on the effects of thiophanate-methyl on the liver and thyroid of rats showed liver enzyme induction, reductions in thyroid hormones (triiodothyronine and thyroxine), and increases in the level of thyroid-stimulating hormone and in thyroid and liver weights. Thyroid hypertrophy and increases in thyroid-stimulating hormone levels associated with treatment with thiophanate-methyl were suppressed by concomitant treatment with thyroxine. Thiophanate-methyl was shown to inhibit porcine thyroid microsomal peroxidase, an enzyme involved in thyroid hormone synthesis. The thyroidal and hepatic changes, including tumours, observed in the studies of toxicity may be due to increased hepatocyte turnover, reductions in the thyroid hormones triiodothyronine and thyroxine as a result of liver enzyme induction, and inhibition of thyroid microsomal peroxidase. Workers involved in manufacturing products containing thiophanate-methyl showed no treatment-related adverse local (skin or eyes) or systemic effects. An ADI of 0-0.02 mg/kg bw was established on the basis of the NOAEL of 2 mg/kg bw per day for developmental toxicity in rabbits and a safety factor of 100. The Meeting noted that the use of thiophanate-methyl on crops gives rise to residues of carbendazim, although thiophanate-methyl can also be detected as part of the residue to which consumers of treated produce are exposed. Since the toxicity of thiophanate-methyl is qualitatively and quantitatively (when corrected for relative molecular mass) different from that of carbendazim, the Meeting concluded that the intake of residues in food should initially be compared with the ADI for thiophanate-methyl. If further refinement of the risk assessment is necessary, the different components of the residue (carbendazim and thiophanate-methyl) may be characterized. Toxicological evaluation Levels that cause no toxic effect Mouse: 150 ppm, equal to 29 mg/kg bw per day (18-month study of toxicity and carcinogenicity) 1000 mg/kg bw per day (maternal toxicity and teratogenicity in study of reproductive toxicity) 500 mg/kg bw per day (fetotoxicity in study of developmental toxicity) Rat: 200 ppm, equal to 9 mg/kg bw per day (two-year study of toxicity and carcinogenicity) 160 ppm, equivalent to 8 mg/kg bw per day (study of reproductive toxicity) 1000 mg/kg bw per day (teratogenicity and fetotoxicity in study of developmental toxicity) 300 mg/kg bw per day (maternal toxicity in a study of developmental toxicity) Rabbit: 2 mg/kg bw per day (maternal toxicity and teratogenicity in study of developmental toxicity) Dog: 10 mg/kg bw per day (studies of toxicity up to two years) Estimate of acceptable daily intake for humans 0-0.02 mg/kg bw Studies that would provide information useful for continued evaluation of the compound 1. Comparison of the metabolism of thiophanate-methyl and carbendazim in different species, including humans 2. Further observations in humans Toxicological criteria for setting guidance values for dietary and non-dietary exposure to thiophanate-methyl Exposure Relevant route, study type, species Results, remarks Short-term (1-7 days) Oral, toxicity, rat LD50 = 7000 mg/kg bw Dermal, toxicity, rat LD50 > 10 000 mg/kg bw Dermal, irritation, rabbit Not irritating Ocular, irritation, rabbit Mildly irritating Dermal, sensitization, guinea-pig Sensitizing in maximization test; not sensitizing in Buehler test Inhalation, toxicity, rat LC50 = 1.8 mg/litre air Mid-term (1-26 weeks) Oral, reproductive toxicity, rabbit NOAEL = 2 mg/kg bw per day; maternal and developmental toxicity Long-term (> one year) Dietary, toxicity and carcinogenicity, NOAEL = 9 mg/kg bw per day; thyroid rumours two years, rat and hepatotoxicity Oral, toxicity, two years, dog NOAEL = 10 mg/kg bw per day; hepatotoxicity and thyroid effects References Aizawa, T. (1991) Human handling experiences from plant employees manufacturing Topsins (3). Unpublished report No. RD-9153 from Nippon Soda Co. Ltd. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Auletta, CS. (1991) A subchronic (3-month) oral toxicity study in the dog via capsule administration with thiophanate-methyl. Unpublished report Project No. 89-3525 (RE-9119) from Bio/dynamics Inc. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Auletta, C.S. (1992) A chronic (1-year) oral toxicity study in the dog via capsule administration with thiophanate-methyl. Unpublished report Project No. 89-3526 (RD-9207) from Bio/dynamics Inc. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Barale, R., Scapoli, C., Meli, C., Casini, D., Minunni, M., Marrazzini, A., Loprieno, N. & Barrai, I. (1993) Cytogenetic effects of benzimidazoles in mouse bone marrow. Mutat. Res., 300, 15-28. Douch, P.G.C. (1974) The metabolism of some thioureidobenzene fungicides in mice and sheep. Xenobiotica, 4, 457-475. Fujino, A., Ohnuma, N., Mori, T., Tanoue, T. & Kamimura, H. (1973) The balance and metabolism studies of thiophanate-methyl in animals. Unpublished report from the Nisso Institute for Life Science, Nippon Soda Co. Ltd, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Hashimoto, Y. (1972) Final report on chronic oral toxicity studies on thiophanate-methyl, dimethyl 4,4'-O-phenylene bis 3-thioal- lophanate in Sprague-Dawley strain rats. Unpublished report from the Nisso Institute for Life Science, Nippon Soda Co. Ltd, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Hashimoto, Y., Makita, T., Nishibe, T., Mori, T., Ohnuma, N., Noguchi, T. & Ohta, G. (1973) Subacute toxicity of thiophanate-methyl in mice and rats. Pharmacometrics, 7, 929-945. Ikeda, K. (1978) Human handling experiences from plant employees manufacturing Topsin (2). Unpublished report from Nippon Soda Co. Ltd. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Kanaguchi, Y. & Nishibe, T. (1990) Thiophanate-methyl reverse mutation study on bacteria. Unpublished report No. RD-9065 from Nippon Soda Co. Ltd. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Kosaka, S. (1973) The report on the carcinogenesis studies of thiophanate-methyl, dimethyl 4,4'-O-phenylene bis-(3-thioal- lophanate) in mice of ICR-SLC strain for 24 months. Unpublished report from the Nisso Institute for Life Science, Nippon Soda Co. Ltd, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co., Ltd, Tokyo, Japan. Makita, T., Hashimoto, Y. & Noguchi, T. (1973) Mutagenic, cytogenetic and teratogenic studies on thiophanate-methyl. Toxicol. Appl. Pharmacol., 24, 206-215. Mochizuki, N. (1993) Topsin M skin sensitization study in guinea pigs. Unpublished report No. RD-9347 from Nippon Soda Co. Ltd. Submitted to WHO by Nippon Soda Co., Ltd, Tokyo, Japan. Mori, H. (1972) Human handling experiences from plant employees manufacturing Topsin (1). Unpublished report from the Fine Chemical Division, Nippon Soda Co. Ltd. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Muller, W. (1993) Topsin M two generation oral (dietary administration) reproduction toxicity study in the rat. Unpublished report HLA Study No. 683-004 (RD-9329) from Hazleton Deutschland GmbH. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Muller, W. & Singer, A. (1995) Topsin M final addendum histopathology report and peer review pathology report to MRID 42899101. Two generation oral (dietary administration) reproduction toxicity study in the rat. Unpublished report HLA Study No. 683-004 addendum histopathology report (RD-9525) from Hazleton Deutschland GmbH. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Murli, H. (1988) Mutagenicity test on Topsin M technical (thiophanate- methyl) in an in-vitro cytogenetic assay measuring chromosomal aberration frequencies in Chinese hamster ovary (CHO) cells. Unpublished report HLA Study No 10345-0-437 (RD-9120) from Hazleton Laboratories America, Inc. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Myhr B.C. (1981) Primary rat hepatocyte unscheduled DNA synthesis assay of thiophanate-methyl. Unpublished report No. LBI Project No 21191 (RD-8195) from Litton Bionetics. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Nishibe, T. (1987) Thiophanate-methyl: Acute inhalation toxicity study in rats. Unpublished report No. RD-8711 from the Toxicology Institute, Environmental Toxicology Laboratory, Nippon Soda Co. Ltd, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Nishibe, T. & Takaori, H. (1990) Summary of mechanistic investigation of the effect of thiophanate-methyl on thyroid and liver. Unpublished report from the Toxicology Institute, Environmental Toxicology Laboratory, Nippon Soda Co. Ltd, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Noguchi, T. (1970a) Toxicological evaluation of thiophanate-methyl (V). Some pharmacological properties of a new fungicide, thiophanate-methyl. Unpublished report from the Nisso Institute for Life Sciences, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Noguchi, T. (1970b) Studies on the biotransformation of thiophanate- methyl in animal and plant (Part 1). Unpublished report from the Chemical Research Laboratories, Nisso Institute for Life Sciences, Kanagawa-ken, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Noguchi, T. (1970c) Toxicological evaluation of thiophanate-methyl (IV). Studies on the teratogenic effect of thiophanate-methyl upon the fetus of ICR strain of mice. Unpublished report from the Nisso Institute for Life Sciences, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Noguchi, T. (1971) Studies on the biotransformation of thiophanate-methyl in animal, plant and soil (Part II). Unpublished report from the Chemical Research Laboratories, Nisso Institute for Life Sciences, Kanagawa-ken, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Noguchi, T. (1972) Studies on the biotransformation of thiophanate-methyl in animal and plant. Unpublished report from the Chemical Research Laboratories, Nisso Institute for Life Sciences, Kanagawa-ken, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Noguchi, T. & Hashimoto, Y. (1970a) Toxicological evaluation of thiophanate-methyl (I). Acute and subacute toxicity of thiophanate-methyl. Unpublished report from the Nisso Institute for Life Sciences, Kanagawa-ken, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Noguchi, T. & Hashimoto, Y. (1970b) Toxicological evaluation of thiophanate-methyl (II). Studies on the subchronic oral toxicity of thiophanate-methyl in mice. Unpublished report from the Nisso Institute for Life Sciences, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Noguchi, T. & Hashimoto, Y. (1970c) Toxicological evaluation of thiophanate-methyl (III). Studies on the subchronic oral toxicity of thiophanate-methyl in rats. Unpublished report from the Nisso Institute for Life Sciences, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Palmer, A., Lovell., M. & Newman, A. (1972) Effect of thiophanate-methyl on reproductive function of multiple generations in the rat. Unpublished report from Huntingdon Research Centre, Huntingdon, Cambs, United Kingdom. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Rodwell, D.E. et al (1981) Teratology study in thiophanate-methyl in rats. Unpublished report No. 449-006 (RD-8126) from International Research and Development Corporation, Mattawan, Michigan, USA. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Ross, F.W. et al. (1986) Thiophanate-methyl: Teratology study in the rabbit. Unpublished report No. 86/NIS010/11 (RD-8642) from Life Science Research. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Saike, O. & Nishibe, T. (1987) Thiophanate-methyl: Acute inhalation toxicity study in rats. Unpublished report No. 0219 from Nisso Institute for Life Sciences, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Shirasu, Y. et al. (1976) Mutagenicity testing on thiophanate-methyl in microbial systems. Unpublished report No. RD-8084 from the Institute of Environmental Toxicology. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Singh, T. & Garg, B. (1989) Effect of thiophanate-methyl on cardiovascular system. Indian Vet. J., 66, 1116-1119. Souma, S. & Nishibe, T. (1986a) Thiophanate-methyl primary dermal irritation study in rabbits. Unpublished report No. RD-8692 from Nisso Institute for Life Sciences, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Souma, S. & Nishibe, T. (1986b) Thiophanate-methyl primary eye irritation study in rabbits. Unpublished report No. RD-8691 from Nisso Institute for Life Sciences, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Souma, S. & Nishibe, T. (1989) Thiophanate-methyl: Delayed contact hypersensitivity study in guinea pigs. Unpublished report No. RD-8924 from Nisso Institute for Life Sciences, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Souma, S. & Nishibe, T. (1990a) Thiophanate-methyl acute oral toxicity study in rats. Unpublished report No. RD-9083 from Nisso Institute for Life Sciences, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Souma, S. & Nishibe, T. (1990b) Thiophanate-methyl acute dermal toxicity study in rabbits. Unpublished report No. RD-9084 from Nisso Institute for Life Sciences, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Takaori, H. (1993) Thiophanate-methyl combined chronic toxicity/oncogenicity study in rats. Unpublished report No. RD-9327 from Nisso Institute for Life Sciences, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Taniguchi, T. (1972) Final report on the long-term oral toxicity studies of thiophanate-methyl, dimethyl 4,4'-O-phenylene- bis(3-thioallophanate) in beagle-dogs for 24 months. Unpublished report from the Nisso Institute for Life Sciences, Kanagawa, Japan. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Thomas, J. (1974) Actions of pesticides and other drugs on the male reproductive system (EPA-650/1-74-011), Washington DC, US Environmental Protection Agency. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Thomas, J. & Schein, L. (1974) Effects of thiophanate and thiophanate- methyl on the male reproductive system of the mouse. Toxicol. Appl. Pharmacol., 30, 129-133. Tippins, R.S. et al. (1984) Gene mutation in Chinese hamster V79 cells with thiophanate-methyl. Unpublished LSR-RTC Report No. 063013-M-05184 (RD-84109) from Life Science Research. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan. Tompkins, E.C. (1992) Topsin-M (thiophanate-methyl) 18-month dietary oncogenicity study in mice. Unpublished report No. WIL-75024 (RD-9328) from WIL Research Laboratory, Inc. Submitted to WHO by Nippon Soda Co. Ltd, Tokyo, Japan.
See Also: Toxicological Abbreviations Thiophanate-methyl (WHO Pesticide Residues Series 3) Thiophanate-methyl (WHO Pesticide Residues Series 5) Thiophanate-methyl (Pesticide residues in food: 1977 evaluations)